Genetic polymorphism of angiotensin converting enzyme and angiotensin II type 1 receptors and their impact on the outcome of acute coronary syndrome

Ghafil, Fadhaa Abdulameer; Mohammad, Bassim I; Al-Janabi, Hussain S.; Hadi, Najah R.; Al-Aubaidy, Hayder A.

doi:10.1016/j.ygeno.2019.05.028

Cited by 8 publications

(10 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The better Hb response was recently partially reasoned to higher plasma angiotensin II (Ang II) levels in D/D and I/D genotypes compared to the II genotype. 17 …”

Section: Discussionmentioning

confidence: 99%

Haematological Indicators of Response to Erythropoietin Therapy in Chronic Renal Failure Patients on Haemodialysis: Impact of Angiotensin-Converting Enzyme rs4343 Gene Polymorphism

Almaeen

Mostafa‐Hedeab

2021

PGPM

View full text Add to dashboard Cite

“…The better Hb response was recently partially reasoned to higher plasma angiotensin II (Ang II) levels in D/D and I/D genotypes compared to the II genotype. 17 …”

Section: Discussionmentioning

confidence: 99%

Haematological Indicators of Response to Erythropoietin Therapy in Chronic Renal Failure Patients on Haemodialysis: Impact of Angiotensin-Converting Enzyme rs4343 Gene Polymorphism

Almaeen

Mostafa‐Hedeab

2021

PGPM

View full text Add to dashboard Cite

“…were analysed to identify their impacts on acute coronary syndrome Additionally, the CT rs5182 genotype was mildly related to STEMI (OR ¼ 1.1). 79…”

Section: Captoprilmentioning

confidence: 99%

“…Two polymorphisms in the ACE gene (rs4343) and angiotensin II receptor type 1 (AT1R) (rs5182) were analysed to identify their impacts on acute coronary syndrome (ACS) in patients who received captopril. Both the GG rs4343 and GA rs5182 genotypes correlated with ST‐segment elevation myocardial infarction (STEMI) (OR = [GG] 1.7, [GA] 1.5) and non‐ST‐segment elevation myocardial infarction (NSTEMI) (OR = [GG] 3, [GA] 3.8) 79 . Additionally, the CT rs5182 genotype was mildly related to STEMI (OR = 1.1) 79 …”

Section: Pharmacogenomics Of Drug Metabolising Genesmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacogenomics of genetic polymorphism within the genes responsible for SARS‐CoV‐2 susceptibility and the drug‐metabolising genes used in treatment

AL-Eitan

Alahmad

2020

Reviews in Medical Virology

View full text Add to dashboard Cite

Summary The ongoing outbreak of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) represents a significant challenge to international health. Pharmacogenomics aims to identify the different genetic variations that exist between individuals and populations in order to determine appropriate treatment protocols to enhance the efficacy of drugs and reduce their side‐effects. This literature review provides an overview of recent studies of genetic polymorphisms in genes that mediate the SARS‐CoV‐2 infection mechanism (ACE1, ACE2, TMPRSS2 and CD26). In addition, genetic variations in the drug‐metabolising enzyme genes of several selected drugs used in the treatment of COVID‐19 are summarised. This may help construct an effective health protocol based on genetic biomarkers to optimise response to treatment. Potentially, pharmacogenomics could contribute to the development of effective high‐throughput assays to improve patient evaluation, but their use will also create ethical, medical, regulatory, and legal issues, which should now be considered in the era of personalised medicine.

show abstract

“…Renin-angiotensin system (RAS) primarily constitutes angiotensinogen, renin, angiotensin I (AT-I), angiotensin-converting enzyme (ACE), angiotensin II (AT-II) along with angiotensin II receptor subtypes 1, 2, 3, and 4 (AT1R, AT2R, AT3R, and AT4R). In recent studies, various genes have been identified in RAS (5,6). Polymorphisms in these genes have been shown to play a role in the pathophysiology of CAD possibly through potent vasoconstrictive and other multifaceted effects of angiotensin II.…”

mentioning

confidence: 99%

Association of angiotensin II type 1 receptor A1166C gene polymorphisms with coronary artery disease in Thrace region of Turkey

Taylan¹

2020

Erciyes Med J

View full text Add to dashboard Cite

Genetic polymorphism of angiotensin converting enzyme and angiotensin II type 1 receptors and their impact on the outcome of acute coronary syndrome

Cited by 8 publications

References 31 publications

Haematological Indicators of Response to Erythropoietin Therapy in Chronic Renal Failure Patients on Haemodialysis: Impact of Angiotensin-Converting Enzyme rs4343 Gene Polymorphism

Haematological Indicators of Response to Erythropoietin Therapy in Chronic Renal Failure Patients on Haemodialysis: Impact of Angiotensin-Converting Enzyme rs4343 Gene Polymorphism

Pharmacogenomics of genetic polymorphism within the genes responsible for SARS‐CoV‐2 susceptibility and the drug‐metabolising genes used in treatment

Association of angiotensin II type 1 receptor A1166C gene polymorphisms with coronary artery disease in Thrace region of Turkey

Contact Info

Product

Resources

About